Nano-Ghosts: Biomimetic membranal vesicles, technology and characterization.
A549 Cells
Bioengineering
/ methods
Biological Transport
Biomimetic Materials
/ chemistry
Cell Membrane
/ chemistry
Drug Compounding
/ methods
Drug Delivery Systems
/ methods
Drug Liberation
Electroporation
/ methods
Extracellular Vesicles
/ chemistry
Green Fluorescent Proteins
/ genetics
Humans
Imatinib Mesylate
/ metabolism
Kinetics
Mesenchymal Stem Cells
/ chemistry
Nanostructures
/ chemistry
Peptides
/ metabolism
Sonication
/ methods
Staining and Labeling
/ methods
Cancer drug delivery
Membrane-based nanoparticles
Mesenchymal stem cells
Nano-Ghosts
Nanovesicles
Journal
Methods (San Diego, Calif.)
ISSN: 1095-9130
Titre abrégé: Methods
Pays: United States
ID NLM: 9426302
Informations de publication
Date de publication:
01 05 2020
01 05 2020
Historique:
received:
03
10
2019
revised:
20
11
2019
accepted:
25
11
2019
pubmed:
4
12
2019
medline:
5
6
2021
entrez:
4
12
2019
Statut:
ppublish
Résumé
Currently, nano-carriers for anti-cancer drug delivery are complex systems, which struggle with immunogenicity and enhanced permeability effect (EPR)-related problems that halt the clinical translation of many therapeutics. Consequently, a rapidly growing field of research has been focusing on biomimetic nano-vesicles (BNVs) as an effective delivery alternative. Nevertheless, the translation of many BNVs is limited due to scalability problems, inconsistent production process, and insufficient loading efficiency. Here we discuss the process of our previously published BNVs, termed Nano-Ghosts (NGs), which are produced from the membrane of mesenchymal stem cells. We demonstrate the flexibility of the process, while alternating physical methodologies (sonication or extrusion) to produce the NGs while preserving their desired characteristics. We also show that our NGs can be labeled using multiple methods (fluorescence, radiolabeling, and genetic engineering) for tracking and diagnostic purposes. Lastly, we demonstrate that the loading efficiency can be improved by using electroporation to accommodate a range of therapeutics (small molecules, peptides and DNA) that can be delivered by the NGs. Our results emphasize the robustness of the NGs technology, its versatility and a vast range of applications, differentiating it from other BNVs and leading the way towards clinical translation.
Identifiants
pubmed: 31794834
pii: S1046-2023(19)30270-1
doi: 10.1016/j.ymeth.2019.11.013
pii:
doi:
Substances chimiques
Peptides
0
Green Fluorescent Proteins
147336-22-9
Imatinib Mesylate
8A1O1M485B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
126-134Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.